Quarterly report pursuant to Section 13 or 15(d)

Strategic Alliances (Details)

v3.8.0.1
Strategic Alliances (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 14 Months Ended 79 Months Ended
May 31, 2016
Jan. 31, 2015
Dec. 31, 2010
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Jun. 30, 2017
Jun. 30, 2017
Dec. 31, 2016
Jul. 31, 2015
Mar. 31, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Revenue from transfer of intellectual property and other       $ 11,665,000 $ 18,441,000 $ 58,819,000 $ 105,338,000          
Deferred revenue       $ 120,400,000   120,400,000       $ 162,400,000    
VFMCRP                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Milestone revenue recognized               $ 0        
VFMCRP | Development and License Agreement                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
License revenue, initial payment $ 50,000,000       50,000,000              
Royalty revenue, obligation period after first product sale 10 years                      
VFMCRP | Regulatory Milestones                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Additional milestone payment to be received $ 37,000,000                      
VFMCRP | Launch and Sales-based Milestones                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Additional milestone payment to be received 195,000,000                      
VFMCRP | Exclusive Option                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Additional milestone payment to be received $ 555,000,000                      
Pfizer | Collaborative Arrangement, Product                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Additional milestone payment to be received   $ 275,000,000.0                    
Increase In Expected Revenue Recognition Performance Period       1 year                
Non-refundable and non-creditable upfront payment   295,000,000                    
Revenue from transfer of intellectual property and other       $ 11,200,000 $ 17,700,000 46,500,000 53,000,000          
Deferred revenue       112,300,000   112,300,000            
Tesaro                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Milestone revenue recognized           10,000,000.0 $ 0          
Upfront payment under license agreements     $ 6,000,000.0                  
Milestone payment received                 $ 30,000,000      
Additional milestone payment     $ 85,000,000                  
Period from first commercial sale     12 years                  
Accrued Expenses | Pfizer | Collaborative Arrangement, Product                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Deferred revenue       44,900,000   44,900,000            
Other Noncurrent Liabilities | Pfizer | Collaborative Arrangement, Product                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Deferred revenue       $ 67,400,000   $ 67,400,000            
Minimum | Pfizer | Collaborative Arrangement, Product                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Each milestone payment   20,000,000.0                    
Maximum | Pfizer | Collaborative Arrangement, Product                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Each milestone payment   $ 90,000,000.0                    
Pharmsynthez                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Ownership percentage, equity method       9.00%   9.00%            
Rxi Pharmaceuticals Corporation                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Maximum milestone payments to be received                       $ 50,000,000.0
Pharmsynthez Note Receivable | Notes | Pharmsynthez                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Debt face amount                     $ 3,000,000.0